1 / 8

Retinal Biologics Market

The retinal biologics market was valued at USD 20.13 billion in 2022 and is expected to reach USD 47.11 billion in 2030, with a CAGR of 11.20% during the forecast period.

sonali58
Download Presentation

Retinal Biologics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Retinal Biologics Market

  2. Retinal biologics refers to the pharmaceutical sector focused on the development, production, and distribution of biological therapies designed to address various retinal disorders and conditions. These biologics are often intricate, utilizing living organisms or components derived from living systems to target specific molecular or cellular pathways associated with retinal diseases. • Retinal biologics market include the prevalence of retinal diseases, advancements in biotechnology, regulatory frameworks, and ongoing research and development initiatives. Challenges may include regulatory hurdles, production complexities, and the need for skilled professionals. Overall, the retinal biologics market represents a crucial frontier in medical innovation, offering the potential for improved therapeutic outcomes and vision care for individuals affected by various retinal disorders. Download Sample PDF

  3. Market Drivers The rising prevalence of retinal diseases is propelling the growth of the market. 1 The aging global population serves as a significant driver for the Retinal Biologics Market. 2 2 2

  4. Market Segmentation 1 • On the basis of drug class, the sub-markets include TNF-alpha inhibitor, and VEGF-A antagonist. 2 • On the basis of indication, the sub-markets include macular degeneration, diabetic retinopathy, and uveitis. 3 • On the basis of distribution channel, the sub-markets include hospitals, clinics, and pharmacies.

  5. Segmentation by Region

  6. Leading Market Players • Regeneron Pharmaceuticals, Inc. • F. Hoffmann-La Roche Ltd • AbbVie Inc. • Amgen Inc. • MeiraGTx Limited • Novartis AG • CoherusBioSciences, Inc. • Bayer AG • Oxurion NV • Nestlé

  7. 2nd Floor, Ganadish Empire, Contact: Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027 Call Us: +91 99239 50043  Mail: info@infiniumglobalresearch.com Web: www.infiniumglobalresearch.com

  8. Thank You!!

More Related